全MRI兼容平台立体定向激光杏仁核海马切除术的精度与初步结局
该单中心回顾性研究纳入2013年6月至2019年10月在Emory大学使用ClearPoint平台行SLAH的91例MTLE患者(97次手术,114条轨迹),评估靶点精度与12个月Engel结局。总体平均靶点误差1.2±1.0 mm,误差随时间显著改善;12个月时50.5%达Engel I级,有MTS者56%达Engel I级。
要点
- ClearPoint平台SLAH总体平均靶点误差1.2±1.0 mm,存在学习效应。
- 12个月Engel I级占50.5%,有MTS者56%、无MTS者32%。
- 该技术可安全消融致痫组织,结局与开放手术相当。
核心结论
- 使用MRI兼容靶向平台行初始SLAH可安全消融致痫组织,癫痫结局与开放手术相当。
研究设计与样本
- 单中心回顾性研究,纳入2013年6月至2019年10月Emory大学连续91例MTLE患者,共97次SLAH、114条轨迹。
主要发现
- 总体平均靶点误差1.2±1.0 mm(范围0.1-4.7 mm),误差随时间显著改善。
- 入点至靶点距离106.5±11.5 mm(范围62.6-127.3 mm),与误差无相关性。
- 12个月随访时Engel I级46例(50.5%)、II级21例(23.1%)、III级16例(17.6%)、IV级5例(5.5%),3例失访。
- 66例MTS患者中12个月Engel I级38例(56%)、II级15例(23%)、III级9例(14%)、IV级3例(4.5%),1例失访。
- 25例无MTS患者中12个月Engel I级8例(32%)、II级6例(24%)、III级7例(28%)、IV级2例(8.0%),2例失访。
临床怎么用
- SLAH可作为MTLE的微创治疗选择,尤其适用于有MTS的患者。
- 术中应关注靶点精度,随着经验积累误差可改善。
局限性
- 回顾性单中心设计。
- 样本量有限,部分患者失访。
- 需进一步验证其相对于现有立体定向技术的优势及多次微创手术的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Minimally invasive MRI-guided laser interstitial thermal therapy (MRgLITT) is an approach increasingly recognized as an effective tool for treating epileptic foci. Recent literature reports that stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) results in seizure-freedom rates comparable to those of analogous open selective amygdalohippocampectomy with a potentially more favorable neurocognitive adverse effect profile. However, many SLAH series show heterogenous results. The authors' objectives were to present the largest experience to date using a single MRI-compatible targeting platform (ClearPoint) for SLAH to treat MTLE and to report their analysis of accuracy and intraoperative factors correlated to complications and initial outcomes. METHODS: The authors retrospectively collected data from all consecutive patients who underwent SLAH for MTLE using a single MRI-compatible targeting platform (ClearPoint) for SLAH at Emory University between June 2013 and October 2019. Univariable analysis, including the Student t-test, 1-way ANOVA, chi-square test, and Wilcoxon rank-sum test, was used to assess the relationship between surgical characteristics and outcomes. RESULTS: The authors analyzed a total of 91 patients who underwent 97 procedures with 114 total trajectories between June 2013 and October 2019. All patients had a diagnosis of MTLE, as determined by scalp or intracranial EEG, with a mean ± SD age at surgery of 42.8 ± 12.9 years and a mean seizure onset age of 19.3 ± 14.7 years. The mean number of trajectories was 1.39 ± 0.6 (range 1-3), with an overall mean target error of 1.2 ± 1.0 mm (range 0.1-4.7 mm). Target errors improved significantly over time, demonstrating a learning effect. Entry-to-target distance was 106.5 ± 11.5 mm (range 62.6-127.3 mm) and did not correlate to error. At the 12-month follow-up, 46 (50.5%) had an Engel score I, 21 (23.1%) had an Engel score II, 16 (17.6%) had an Engel score III, 5 (5.5%) had an Engel score IV, and 3 were lost to follow-up. Of the 66 patients who had mesial temporal sclerosis (MTS), 38 (56%) had Engel score I, 15 (23%) had score II, 9 (14%) had score III, and 3 (4.5%) had score IV at 12 months, with 1 lost to follow-up. Of the 25 patients without MTS, 8 (32%) had Engel score I, 6 (24%) had score II, 7 (28%) had score III, and 2 (8.0%) had score IV at 12 months, with 2 lost to follow-up. CONCLUSIONS: The authors present the largest single-center experience using an MRI-compatible targeting platform for initial SLAH to treat MTLE. This technique results in safe laser ablation of epileptogenic tissue, with seizure outcomes comparable to those reported for open procedures. Further work is needed to validate its advantages over existing stereotactic approaches and the impact of multiple minimally invasive procedures.
引用
- Sun Y, Isbaine F, Bentley JN, et al. Accuracy and initial outcomes for stereotactic laser amygdalohippocampotomy using a fully MRI-compatible platform. J Neurosurg. 2025. PMID: 40344759. doi:10.3171/2024.12.JNS241158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。